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bjectives The purpose of this study was to evaluate the safety and effectiveness of the SeptRx
atent foramen ovale (PFO) closure device (SeptRx, Inc., Fremont, California).
ackground A PFO is a relatively common remnant of the fetal circulation that can be associated
ith cryptogenic stroke, transient ischemic attack, migraine, or decompression sickness. Percutane-
us PFO closure with different devices has been performed for many years. However, most of the
ommon devices leave a relatively large amount of material in the left and right atria. The SeptRx
FO device (SeptRx, Inc.) is the ﬁrst PFO closure device designed to ﬁt directly into the pocket of
he PFO.
ethods From July 2006 to May 2007, 13 patients between 18 and 65 years of age with a history
f cryptogenic stroke or transient ischemic attack were included into this ﬁrst-in-man trial. All pa-
ients received 100 mg aspirin and 75 mg clopidogrel for 6 months. Follow-up was done at 1 and 6
onths after procedure with transesophageal echocardiography and transcranial Doppler.
esults In 11 of 13 patients, PFO closure with the SeptRx device was successfully performed. In 2
atients, PFO closure with this device was not possible due to the anatomy of the PFO; 1 device
as retrieved before release, and the other was recaptured with a snare. After 30 days, 6 of the 11
FOs were closed; after 6 months, all were closed. No adverse events occurred.
onclusions The SeptRx PFO closure device appears to be safe and effective. The advantage of this
ccluder is that there is only minimal foreign material on the left and right sides of the interatrial
eptum. This is the ﬁrst such “in-tunnel” PFO closure device. (J Am Coll Cardiol Intv 2010;3:963–7)
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964patent foramen ovale (PFO) is a tunnel-like defect
ounded by the septum primum and septum secundum
onnecting the right and left atria (1). The length of the
unnel can vary widely, according to Marshall and Lock (2),
etween 2.4 and 19.5 mm. In the fetal period, the foramen
vale is a physiological pathway from the right to the left
trium for blood to bypass the lungs. In the first days after
irth, the foramen ovale should close, but in 25% to 30% of
eople it does not fully close (3). This can lead to stroke or
ransient ischemic attack (TIA) by providing a right to left
hunt for the passage of emboli into the arterial circulation.
atent foramen ovales are also found more frequently in
atients suffering from migraine with or without aura (4–6)
nd those with decompression sickness (7).
Percutaneous PFO closure has been successfully per-
ormed since the 1980s with different kinds of devices (8).
losure, however, might be complicated by thrombus for-
ation on the device or atrial fibrillation (9).
ethods
tudy design. The feasibility study was designed as a pro-
pective, single-center, first-in-human trial. The study was
sponsored by Nitinol Devices
and Components (NDC, Fre-
mont, California). It was ap-
proved by the local ethics com-
mittee, and all patients provided
written informed consent.
Patients with a history of
cryptogenic stroke or TIA be-
ween 18 and 65 years of age were included in the trial. The
FO size had to be between 5 and 12 mm in width and
etween 3 and 30 mm in length, as evaluated by balloon
izing. Patients with additional atrial septal defects, other
eart abnormalities, or history of arrhythmia were excluded,
s were patients with active endocarditis or thrombus near
he PFO.
Tables 1, 2, and 3 show the patient demographic data, the
FO demographic data, and the qualifying event for inclu-
ion in the study.
Mean PFO diameter in this study was 7.6 mm ( 2.1
m SD; range 4.9 to 11.3 mm). Four patients were found
o have an atrial septum aneurysm. During follow-up, 2 of
hese 4 had a residual shunt—1 small, and the other
oderate in size. None of them had a multifenestrated
eptum. All PFOs had a diameter between 5 and 12 mm.
ne patient had to be excluded because the tunnel was
horter than 5 mm, and another 1 had to be excluded
ecause the tunnel was longer than 12 mm.
evice and implantation technique. At the time of device
mplantation, all patients were given heparin, antibiotics,
spirin (100 mg), and clopidogrel (75 mg). The PFO
bbreviations
nd Acronyms
FO  patent foramen ovale
IA  transient ischemic
ttackalloon sizing was performed according to standard tech- fliques. Transesophageal echocardiography and fluoroscopy
ere performed during the implantation.
The SeptRx PFO closure device (SeptRx, Inc., Fremont,
alifornia) consists of a laser-cut, electropolished, self-
xpanding Nitinol frame with flexible anchor struts at the
op of the device, which uncoil from their curved shape to
dapt to a variety of PFO tunnel lengths.
At the base of the device are additional anchors, which
re designed to grip the edge of the PFO tunnel on the right
trial side. Only 1 size of the SeptRx device (device width:
4 mm, device length: 14 mm) was used in this study. Both
he left and right atrial anchors are surrounded by a fine coil
f tantalum for radiopacity. The interior of the device
ontains a fine-wire braided Nitinol mesh (NDC). The
esh is intended to stimulate the body’s natural adhesion
esponse for permanent closure of the PFO, and it also
rovides an immediate barrier to the conduction of emboli
efore permanent closure (Fig. 1).
The device is delivered over a guidewire through the
nferior vena cava to the right atrium and across the PFO.
he delivery system is compatible with a 0.035-inch guide-
ire and deliverable through a 9-F sheath. The device is
onnected to the delivery system by 2 positive “paddle”
ocks. These paddle locks ensure full control of the SeptRx
mplant (SeptRx, Inc.) until it is released by a simple
humbscrew release mechanism. The body of the delivery
ystem is constructed of coaxial flexible tubes that provide
xcellent torque control for precise positioning of the device.
he device might be recaptured into the original delivery
heath at any time of the procedure for repositioning or
ecovery.
Figure 2 demonstrates the SeptRx device with trans-
sophageal echocardiography during the 6-month follow-
p. Figures 3 and 4 demonstrate the implantation steps on
Table 1. Patient Demographic Data (n  13)
Age, yrs 52 13
Gender 46% male
Risk factors, n
History of smoking 2
History of hypertension 6
History of hypercholesterolemia 2
History of deep vein thrombosis 0
History of diabetes mellitus 1 with gestation diabetes mellitus
History of arrhythmia 0
Concomitant diseases, n
History of chronic heart failure 0
History of migraine 0
History of gastrointestinal bleeding 0
History of COPD 0
COPD chronic obstructive pulmonary disease.uoroscopy.
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965anagement after implantation. All patients received 100
g aspirin and 75 mg clopidogrel for 6 months after
mplantation. They were advised to take endocarditis pro-
hylaxis in case of exposure for 6 months. Patients were seen
or follow-up at 30 days and 6 months after the implanta-
ion. Follow-up investigations included physical examina-
ion, electrocardiogram, transcranial Doppler, and trans-
sophageal echocardiography with a contrast bubble study.
esults
evice implantation was successful in 11 of 13 patients.
ne patient had a very short tunnel, and after implantation
he device was mostly sitting in the right atrium, so it was
ecaptured with a snare. This patient received an Amplatzer
FO occluder (AGA Medical Corp., Plymouth, Minne-
ota). The other patient had a very long tunnel, and it was
ot possible to place the SeptRx device correctly, so it was
ecaptured before release, and the PFO was closed with a
remere occluder (St. Jude Medical, St. Paul, Minnesota).
losure rates. At the 30-day follow-up, 5 patients (45%)
resented with a residual shunt. Four of them had a
inimal shunt (5 to 10 bubbles), and 1 had a moderate
hunt (10 to 30 bubbles). The 6-month follow-up showed
hat all PFOs were closed.
dverse events. During the 6 months of follow-up, no
eaths, no strokes, no TIAs, no thrombus formation, no
rrhythmias, no infections or hemopericardium, and no
ther serious adverse events occurred.
iscussion
umerous transcatheter PFO closure systems are commer-
ially available or under investigation. Some of the double
mbrella devices leave a relatively large amount of foreign
aterial in the atria, which can lead to thrombus formation
n the device (9,10). We reported in a study with 1,000
atients that the incidence of thrombus formation is 2% (9).
urthermore, distortion of the septum due to a wire might
e the cause of atrial fibrillation in some patients.
Table 2. PFO Morphology (n  13)
PFO mean diameter (mm) 7.6 2.1; 4.9–11.3
Atrial septal aneurysm (n) 4
Septum excursion range (mm) 7.5 1.4; 6.6–9.0
Valvula eustachii (n) 4
PFO patent foramen ovale.
Table 3. Qualifying Event
History of stroke 5
History of transient ischemic attack 7History of decompression sickness 1One of the advantages of the SeptRx device is the
inimal material in the left atrium. So far, no thrombus
ormation has occurred, and the unique design of the device
ight help to minimize chronic complications such as
hrombus formation or atrial fibrillation. A few other new
evices are designed to minimize the incidence of thrombus
ormation. The BioSTAR device (NMT Medical, Boston,
assachusetts), reported by Mullen et al. (11), is a bioab-
orbable septal repair device that is mostly replaced with
ealthy native tissue. According to the authors, 90% to 95%
Figure 1. The SeptRx Device Attached to Its Delivery System
The longer anchors are on the left atrial side and are designed to uncoil to
accommodate a range of patent foramen ovale (PFO) tunnel lengths. The
interior of the device contains a ﬁne-wire braided Nitinol mesh, which pro-
vides an immediate barrier to the conduction of emboli and is intended to
stimulate the body‘s natural adhesion response for permanent closure of
the PFO.
Figure 2. Transesophageal Echocardiography 6 Months After PFO Closure
The device is sitting with at least two-thirds of its length in the tunnel. This
is minimizing the material in the left atrium. During follow-up, Valsalva
maneuver was done. Abbreviation as in Figure 1.
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966f the device is absorbed, and this could also help to
inimize the possibility of thrombus formation.
The Premere device has an open architecture and no
abric covering on the left atrial side, which could reduce the
isk for thrombus formation as well. During the CLOSEUP
rial, no thrombus formation was reported by Büscheck et
l. (12).
Another advantage of the SeptRx device is that it does
ot limit future transeptal puncture through the septum to
he left atrium if it is needed. Instead of covering both sides
f the septum with an umbrella, the SeptRx device sits
lmost entirely in the tunnel.
According to Alaeddini et al. (13), in a study with 71
atients, 5 patients (7%) presented with atrial fibrillation or
utter. The devices used for the study were the Cardio-
EAL (NMT Medical) (28 mm or 33 mm) and the
mplatzer (AGA Medical Corp.). Atrial fibrillation oc-
urred more often in patients with a larger device. Leaving
nly minimal material in the left atrium, the SeptRx device
ould possibly reduce the risk for atrial fibrillation.
Although only 11 patients were treated with the
eptRx device, the 100% closure rate and no major
dverse events are very promising findings. In 2009, von
ardeleben et al. (14) published a study with 357 patients
ndergoing PFO closure with 3 different devices (199
mplatzer, 48 STARFlex [NMT Medical], and 110
elex [W. L. Gore and Assoc., Flagstaff, Arizona]). Five
f the STARFlex patients (10.4%) developed a thrombus
t the device. The overall residual shunt rate at 6-month
ollow-up was 7.6%. Luermans et al. (15) reported 83
atients (63 STARFlex and 20 Amplatzer) in which 11
Figure 3. Fluoroscopy During Implantation Steps
The left atrial anchors are liberated from the delivery sheath, but the right
atrial anchors are still inside. The right atrial anchors will ﬁrst deﬂect inward
as the proximal end of the device enters the tissue; then, the left atrial
anchors will begin to unfurl as they engage with septum secundum.17.4%) of the STARFlex patients developed atrial ar-hythmia after the implantation. Residual shunt rate was
.7% in this study. Taaffe et al. (16) reported a compar-
son of 220 Amplatzer, 220 STARFlex, and 220 Helex
W. L. Gore and Assoc.) implantations. They found
hrombus formation in 8 STARFlex patients and atrial
rrhythmia in 3 Amplatzer, 2 STARFlex, and 2 Helex
atients. The publication of Slavin et al. (17) presented
he results of 131 patients undergoing PFO closure, 101
ith the Amplatzer device and 30 with the CardioSEAL
NMT Medical) device. Thrombus formation at the
evice occurred in 6 of the CardioSEAL patients. The
esidual shunt rate at 6-month follow-up was 10.6%. In a
tudy with 128 Helex occluders, Billinger et al. (18)
ound the development of thrombus formation on the
evice in 9 patients and atrial arrhythmia in 2 patients. A
esidual shunt existed at 6-month follow-up in 15% and
fter 1 year in 11%.
These are the results of the small, prospective first-
n-man trial. This year, a second trial with the SeptRx
evice will be started, hopefully reproducing these good
esults.
onclusions
his study showed that PFO closure with the SeptRx device
s technically feasible and safe. Neither device- nor
rocedure-related adverse events occurred, and PFO closure
as achieved in 100% of the patients.
Figure 4. The SeptRx Device Completely Released From Its
Delivery System
If the SeptRx implant is not satisfactorily placed in the patent foramen
ovale, it can be recaptured into the Mullins sheath, and the deployment
and positioning processes can be repeated. After implantation contrast
injection was done.
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